Nature Communications (Sep 2021)
9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy
- Guangchun Han,
- Guoliang Yang,
- Dapeng Hao,
- Yang Lu,
- Kyaw Thein,
- Benjamin S. Simpson,
- Jianfeng Chen,
- Ryan Sun,
- Omar Alhalabi,
- Ruiping Wang,
- Minghao Dang,
- Enyu Dai,
- Shaojun Zhang,
- Fengqi Nie,
- Shuangtao Zhao,
- Charles Guo,
- Ameer Hamza,
- Bogdan Czerniak,
- Chao Cheng,
- Arlene Siefker-Radtke,
- Krishna Bhat,
- Andrew Futreal,
- Guang Peng,
- Jennifer Wargo,
- Weiyi Peng,
- Humam Kadara,
- Jaffer Ajani,
- Charles Swanton,
- Kevin Litchfield,
- Jordi Rodon Ahnert,
- Jianjun Gao,
- Linghua Wang
Affiliations
- Guangchun Han
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center
- Guoliang Yang
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
- Dapeng Hao
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center
- Yang Lu
- Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center
- Kyaw Thein
- Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center
- Benjamin S. Simpson
- Tumour Immunogenomics and Immunosurveillance Laboratory, University College London Cancer Institute
- Jianfeng Chen
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
- Ryan Sun
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center
- Omar Alhalabi
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
- Ruiping Wang
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center
- Minghao Dang
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center
- Enyu Dai
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center
- Shaojun Zhang
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center
- Fengqi Nie
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
- Shuangtao Zhao
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center
- Charles Guo
- Department of Pathology, The University of Texas MD Anderson Cancer Center
- Ameer Hamza
- Department of Pathology, The University of Texas MD Anderson Cancer Center
- Bogdan Czerniak
- Department of Pathology, The University of Texas MD Anderson Cancer Center
- Chao Cheng
- Department of Medicine, Epidemiology and Population Science, Baylor College of Medicine
- Arlene Siefker-Radtke
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
- Krishna Bhat
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center
- Andrew Futreal
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center
- Guang Peng
- Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center
- Jennifer Wargo
- Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center
- Weiyi Peng
- Department of Biology and Biochemistry, University of Houston
- Humam Kadara
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center
- Jaffer Ajani
- Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center
- Charles Swanton
- Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute
- Kevin Litchfield
- Tumour Immunogenomics and Immunosurveillance Laboratory, University College London Cancer Institute
- Jordi Rodon Ahnert
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center
- Jianjun Gao
- Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
- Linghua Wang
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center
- DOI
- https://doi.org/10.1038/s41467-021-25894-9
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 19
Abstract
The molecular mechanisms of resistance to immune checkpoint therapy remain elusive. Here, the authors perform immunogenomic analysis of TCGA data and data from clinical trials for antiPD-1/PD-L1 therapy and highlight the association of 9p21 loss with a cold tumor microenvironment and resistance to therapy.
